作者: Datong Tang , Joel D. Moore , Zhe Wang , Yat Sun Or
DOI:
关键词:
摘要: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, prodrugs thereof, which inhibit serine protease activity, particularly the activity hepatitis C virus (HCV) NS3-NS4A protease. Consequently, interfere with life cycle and are also useful as antiviral agents. further pharmaceutical compositions comprising aforementioned for administration a subject suffering from HCV infection. methods treating an infection in by administering composition compound invention.